Reckitt Benckiser Group (RKT)

Sector:

Household Goods

Index:

FTSE 100

4,859.00p
   
  • Change Today:
      26.00p
  • 52 Week High: 5,872.00p
  • 52 Week Low: 4,093.00p
  • Currency: UK Pounds
  • Shares Issued: 686.62m
  • Volume: 469,238
  • Market Cap: £33,363m

Reckitt Benckiser tumbles on litigation woes

By Michele Maatouk

Date: Monday 29 Jul 2024

LONDON (ShareCast) - (Sharecast News) - Consumer goods giant Reckitt Benckiser tumbled on Monday amid concerns about potential litigation.
At 0910 BST, the shares were down 8.9% at 4,085p, after a US jury found on Friday that infant formula by Abbott Laboratories had caused a girl to develop a dangerous bowel disease. Abbott was ordered to pay $495m in damages. This consisted of $95m compensatory damages and $400m punitive.

Jefferies said in a research note: "This is likely to depress sentiment on the risk for both cited defendants (Reckitt and Abbott) in these claims, we think.

"RKT share price we estimate is already discounting for circa £3/$3.5bn of liability risk next year. But with its own new individual trial due to start on 30 September and multi-district litigation class action gaining momentum, that risk may be extended this week we think."

Jefferies pointed out that the $495m award against Abbott in the latest NEC (necrotizing enterocolitis) case on Friday follows the $60m award against Mead Johnson - which is the Reckitt Nutrition subsidiary - in March.

Dan Coatsworth, investment analyst at AJ Bell, said: "Shares in Reckitt have slumped to their lowest level since January 2013 after negative read across from a court case in the US involving Abbott Laboratories. A court has ordered Abbott to pay $495 million over allegations it hid the risks around its premature infant formula.

"Reckitt's shares have been severely depressed since March as the market worries about the scale of any potential liabilities if the company loses legal battles around the safety of its baby formula.

"A US court case has already awarded $60 million in damages to a mother who said her baby died after consuming Reckitt's Enfamil baby formula. Several hundred similar claims have been in filed in US courts targeting Reckitt and Abbott.

"The more setbacks for either baby formula maker, the more complicated it becomes for Reckitt to sell its nutrition arm. Reckitt last week indicated it might be up for sale, saying it was considering all options for the business.

"Any potential buyer could be put off by the possibility of liabilities from the court cases, meaning the pressure is growing for Reckitt to find a way to ringfence a large amount of money in case it loses big time in the court battles."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Reckitt Benckiser Market Data

Currency UK Pounds
Share Price 4,859.00p
Change Today 26.00p
% Change 0.54 %
52 Week High 5,872.00p
52 Week Low 4,093.00p
Volume 469,238
Shares Issued 686.62m
Market Cap £33,363m

Reckitt Benckiser Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
8.25% above the market average8.25% above the market average8.25% above the market average8.25% above the market average8.25% above the market average
52.38% below the sector average52.38% below the sector average52.38% below the sector average52.38% below the sector average52.38% below the sector average
Price Trend
7.31% above the market average7.31% above the market average7.31% above the market average7.31% above the market average7.31% above the market average
13.04% above the sector average13.04% above the sector average13.04% above the sector average13.04% above the sector average13.04% above the sector average
Income
41.38% above the market average41.38% above the market average41.38% above the market average41.38% above the market average41.38% above the market average
25% below the sector average25% below the sector average25% below the sector average25% below the sector average25% below the sector average
Growth
42.03% above the market average42.03% above the market average42.03% above the market average42.03% above the market average42.03% above the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average

What The Brokers Say

Strong Buy 4
Buy 4
Neutral 9
Sell 0
Strong Sell 1
Total 18
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Reckitt Benckiser Dividends

  Latest Previous
  Interim Final
Ex-Div 01-Aug-24 11-Apr-24
Paid 13-Sep-24 24-May-24
Amount 80.40p 115.90p

Trades for 02-Jan-2025

Time Volume / Share Price
15:36 0 @ 4,884.00p
15:49 0 @ 4,886.00p
15:22 0 @ 4,878.00p
16:47 5,212 @ 4,858.61p
16:38 2 @ 4,859.00p

Reckitt Benckiser Key Personnel

Chair Jeremy Darroch
CEO Kris Licht

Top of Page